Clinical experience of ONC201 in patients with recurrent H3 K27M-mutant spinal cord glioma.
Kurz S, Tarapore R, Odia Y, Butowski N, Koschmann C, Aguilera D, MacDonald T, Lu G, Allen J, Oster W, Mehta M, Chi A, Wen P. Clinical experience of ONC201 in patients with recurrent H3 K27M-mutant spinal cord glioma. Journal Of Clinical Oncology 2020, 38: 2563-2563. DOI: 10.1200/jco.2020.38.15_suppl.2563.Peer-Reviewed Original ResearchSingle agent groupSpinal cord tumorsCombination groupCord tumorsPediatric patientsSpinal cordH3 K27M mutationMedian survival time rangesMedian follow-up timePhase I clinical trialPhase II clinical trialK27M mutationSurvival time rangesClinical experienceSpinal cord gliomasFollow-up timeHigh-grade gliomasII clinical trialsDose reductionDRD2 antagonistsMedian ageProlonged survivalAgent groupDiffuse gliomasUnfavorable prognosis